The half-life of thymidine kinase 1 in serum measured by ECL dot blot: a potential marker for monitoring the response to surgery of patients with gastric cancer.

Thymidine kinase 1 in serum (STK1) of patients with gastric cancer was determined by two methods: ECL dot blot and radioactivity assay. Both measurements showed significantly different values for preoperative STK1 and healthy STK1 (p=0.012 for ECL dot blot and p=0.003 for the radioactivity assay). The preliminary results of ECL dot blot STK1 measurement showed that in tumor-free subjects the level of the enzyme was significantly reduced to 52.7% 35 days after surgery (n=8, p=0.0106). The decrease in STK1 levels in the tumor-free subjects paralleled the decline of the half-life of the STK1 enzyme. In patients with distant metastases (n=6) the enzyme level had increased to 173% 35 days postoperatively. By contrast, with the radioactivity assay no significant differences in thymidine kinase activity for 0-day-postoperative patients and 35-day-postoperative tumor-free patients was found (p=0.329). The activity decreased to 80% in 35-day-postoperative patients with metastatic disease. We suggest that the value of the half-life of STK1 measured by ECL dot blot can be used as a potential marker for monitoring the response to surgery in patients with gastric or other cancers one month after surgery.

[1]  J. Sherley,et al.  Regulation of human thymidine kinase during the cell cycle. , 1988, The Journal of biological chemistry.

[2]  T. Kelly,et al.  Cell cycle regulation of thymidine kinase: residues near the carboxyl terminus are essential for the specific degradation of the enzyme at mitosis , 1991, Molecular and cellular biology.

[3]  T. Fornander,et al.  The Clinical Significance of Thymidine Kinase 1 Measurement in Serum of Breast Cancer Patients Using Anti-TK1 Antibody , 2000, The International journal of biological markers.

[4]  G. Costa,et al.  The role of serum and gastric juice levels of carcinoembryonic antigen, CA19.9 and CA72.4 in patients with gastric cancer , 1998, Journal of Cancer Research and Clinical Oncology.

[5]  T. Hiwasa,et al.  Specific recognition of cytosolic thymidine kinase in the human lung tumor by monoclonal antibodies raised against recombinant human thymidine kinase. , 2001, Journal of immunological methods.

[6]  E. Thiel,et al.  Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. , 1999, Blood.

[7]  K. Chow,et al.  Expression of nm23 in the primary tumor and the metastatic regional lymph nodes of patients with gastric cardiac cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  M. Ychou,et al.  Clinical Significance and Prognostic Value of CA72-4 Compared with CEA and CA19-9 in Patients with Gastric Cancer , 2002, Disease markers.

[9]  S. Eriksson,et al.  Characterization of a peptide antibody against a C-terminal part of human and mouse cytosolic thymidine kinase, which is a marker for cell proliferation. , 1996, European journal of cell biology.

[10]  Jianping Wu,et al.  A Comparative Study: Immunohistochemical Detection of Cytosolic Thymidine Kinase and Proliferating Cell Nuclear Antigen in Breast Cancer , 2002, Cancer investigation.

[11]  S. Eriksson,et al.  Investigation on Cell Proliferation with a New Antibody against Thymidine Kinase 1 , 2001, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.

[12]  B. Tribukait,et al.  Cell cycle related studies on thymidine kinase and its isoenzymes in Ehrlich ascites tumours , 1991, Cell proliferation.

[13]  U. Pettersson,et al.  Application of an in vitro assay for serum thymidine kinase: Results on viral disease and malignancies in humans , 1984, International journal of cancer.